February 13, 2026

Company Name	Synspective Inc.	
Representative	Representative Director & CEO	Motoyuki ARAI
	（Code number：290A TSE Growth）	
Contact	Board director & CFO	Atsushi SHITO (ir@synspective.com)

Notice Regarding the Issuance of the 6th and the 7th Series of Share Acquisition Rights (Stock Options)

Synspective, Inc. (the "Company") hereby announces that at the meeting of its Board of Directors held today, the Company resolved to issue the 6th Series of Share Acquisition Rights for allocation to its employees and the 7th Series of Share Acquisition Rights for allocation to its directors and employees, pursuant to the provisions of Articles 236, 238, and 240 of the Companies Act.

Ⅰ. Purpose and Reason for Offering Share Acquisition Rights

(1) The 6th Series of Share Acquisition Rights

The 6th Series of Share Acquisition Rights will be allotted to the Company's employees for the purpose of securing and retaining personnel who will support the Company's medium- to long-term growth, and of further enhancing their motivation and morale to contribute to medium- to long-term improvement in business performance and corporate value.

(2) The 7th Series of Share Acquisition Rights

The 7th Series of Share Acquisition Rights will be issued for consideration at fair market value to the Company's directors and employees for the purpose of providing incentives aimed at enhancing the Company's medium- to long-term corporate value.

These rights are performance-linked and may only be exercised subject to the achievement of specified performance targets. This is intended to encourage the eligible officers and employees to make a stronger commitment to the Company's sustainable growth and to the achievement of its business plans.

Performance Conditions

Holders of the Share Acquisition Rights who have been allotted such rights may, during the fiscal years from the fiscal year ending December 2027 to the fiscal year ending December 2028, exercise their Share Acquisition Rights up to the exercise ratio specified for each of the items (a) through (e) below, out of the Share Acquisition Rights granted to them, if the total revenue satisfies the relevant condition.

	During the fiscal years from the fiscal year ending December 2027 to the fiscal year ending December 2028	**Exercise ratio**
a.	If total revenue exceeds ¥27,000 million at any time during the assessment fiscal year	60%
b.	If total revenue exceeds ¥28,500 million at any time during the assessment fiscal year	70%
c.	If total revenue exceeds ¥30,000 million at any time during the assessment fiscal year	80%
d.	If total revenue exceeds ¥31,500 million at any time during the assessment fiscal year	90%
e.	If total revenue exceeds ¥33,000 million at any time during the assessment fiscal year	100%

2. Outline of the Share Acquisition Rights

	The 6th Series of Share Acquisition Rights	The 7th Series of Share Acquisition Rights
Allottees	Employees of the Company	Directors and employees of the Company
Number of Share Acquisition Rights	702 Share Acquisition Rights	4,038 Share Acquisition Rights
Class and Number of Shares to Be Issued upon Exercise	70,200 shares of the Company's common stock	403,800 shares of the Company's common stock
Amount to Be Paid in for Share Acquisition Rights	No payment of money is required in exchange for the Share Acquisition Rights	100 yen per Share Acquisition Right
Payment Due	Not Applicable	March 5, 2026
Exercise Price	1 yen per share (nominal consideration)	1,252 Yen per share
Exercise Period	From March 6, 2026 to March 5, 2031	From April 1, 2028 to March 5, 2032
Restrictions on Transfer	Transfer of the Share Acquisition Rights shall be subject to approval by the Board of Directors of the Company.	Transfer of the Share Acquisition Rights shall be subject to approval by the Board of Directors of the Company.

3. Conditions for Exercise of the Share Acquisition Rights

Holders of the Share Acquisition Rights must, at the time of exercising such rights, hold a position as a director or employee of the Company. Any other conditions for exercise shall be as set forth in the share acquisition rights allotment agreement to be entered into between the Company and each holder of the Share Acquisition Rights.

4. Rationale for the Issuance Not Constituting an Offer on Particularly Favorable Terms (The 7th Series of Share Acquisition Rights)

With respect to the Share Acquisition Rights of the 7th Series to be allotted to the Company's directors, based on the valuation results obtained from an independent third-party valuation institution, the amount to be paid in and the exercise price have both been determined to be at fair market value. Accordingly, the issuance is not considered to constitute an offer on particularly favorable terms.

5. Concept Regarding Dilution

If all of the 6th and the 7th Series of the Share Acquisition Rights are exercised, the total dilution ratio against the total number of issued shares will be approximately 0.35%, and the impact on existing shareholders will be limited. On the other hand, as the Share Acquisition Rights are intended to secure and retain personnel who will support the Company's growth and to enhance the Company's medium- to long-term corporate value, we believe that they will contribute to the Company's sustainable growth and enhancement of corporate value. Taking these factors into consideration in a comprehensive manner, the Company has determined that this issuance is reasonable.

(Note) The dilution ratio has been calculated based on the total number of issued shares as of December 31, 2025, taking into account the increase in the number of shares assuming that all of the 6th and the 7th Series of Share Acquisition Rights are exercised.

6. Concept Regarding Future Issuances of Share Acquisition Rights

Looking ahead to future business expansion and medium- to long-term enhancement of corporate value, the Company may consider, as necessary, issuing Share Acquisition Rights to its directors and employees. In doing so, the Company will carefully determine the size, terms and timing of any such issuance after giving due consideration to the dilutive impact on existing shareholders, and will implement such issuances only to the extent that they contribute to the Company's sustainable growth and enhancement of corporate value.

Ⅱ. Terms and Conditions of the 6th Series of Share Acquisition Rights

The detailed terms and conditions of the Share Acquisition Rights are described in the Japanese version and have been omitted from this English translation.

Ⅲ. Terms and Conditions of the 7th Series of Share Acquisition Rights

The detailed terms and conditions of the Share Acquisition Rights are described in the Japanese version and have been omitted from this English translation.

END